Exicure (NASDAQ:XCUR – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
Earnings & Valuation
This table compares Exicure and Protalix BioTherapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exicure | $500,000.00 | 13.76 | -$4.95 million | ($1.32) | -0.80 |
| Protalix BioTherapeutics | $84.69 million | 2.87 | $8.31 million | $0.25 | 11.54 |
Protalix BioTherapeutics has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Exicure and Protalix BioTherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
| Protalix BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
Protalix BioTherapeutics has a consensus price target of $12.00, indicating a potential upside of 315.94%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Exicure.
Insider and Institutional Ownership
42.8% of Exicure shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Exicure and Protalix BioTherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exicure | N/A | -237.91% | -61.98% |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
Volatility & Risk
Exicure has a beta of 3.83, suggesting that its share price is 283% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.01, suggesting that its share price is 99% less volatile than the S&P 500.
Summary
Protalix BioTherapeutics beats Exicure on 8 of the 14 factors compared between the two stocks.
About Exicure
Exicure, Inc. is a biotechnology company historically focused on developing nucleic acid-based therapeutics. Its research has centered on spherical nucleic acid (SNA) technology, a platform designed to deliver genetic material into cells and influence disease-related gene activity. The company has pursued potential treatments for conditions including rare genetic disorders and cancer. Its work has included research into therapies intended to address diseases with limited treatment options. Exicure was based in Chicago, Illinois.
About Protalix BioTherapeutics
Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
